KCG Holdings Inc. purchased a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000. KCG Holdings Inc. owned 0.17% of Galmed Pharmaceuticals as of its most recent SEC filing.
Galmed Pharmaceuticals Ltd. (NASDAQ GLMD) traded up 1.11% on Friday, hitting $8.18. The company’s stock had a trading volume of 19,028 shares. Galmed Pharmaceuticals Ltd. has a 12 month low of $2.78 and a 12 month high of $8.60. The firm’s market cap is $99.95 million. The firm has a 50 day moving average of $6.96 and a 200 day moving average of $5.39.
Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. The company had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.29 million. Galmed Pharmaceuticals had a negative net margin of 1,443.98% and a negative return on equity of 141.13%. Equities research analysts forecast that Galmed Pharmaceuticals Ltd. will post ($0.94) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/12/20473-shares-in-galmed-pharmaceuticals-ltd-nasdaqglmd-acquired-by-kcg-holdings-inc.html.
A number of research analysts have weighed in on the company. Maxim Group set a $9.00 target price on Galmed Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, May 15th. ValuEngine upgraded Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 17th. HC Wainwright upped their target price on Galmed Pharmaceuticals from $12.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a report on Wednesday, August 2nd.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Want to see what other hedge funds are holding GLMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD).
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.